NASDAQ:MNMD

MindMed Urges Shareholders to Vote TODAY for Company Nominees Ahead of June 13th Deadline

Retrieved on: 
Friday, June 9, 2023
Biotechnology, Neurology, Mental Health, Health, Clinical Trials, Medicine, Annual general meeting, NOT, Multimedia, Patient, NEO, MindMed, FCM, Security (finance)

MindMed urges shareholders to vote online ahead of the deadline to ensure that their shares are represented.

Key Points: 
  • MindMed urges shareholders to vote online ahead of the deadline to ensure that their shares are represented.
  • MindMed is confident that its nominees possess relevant backgrounds and expertise to continue overseeing the Company’s strategy and remains focused on its mission to deliver value to patients and shareholders.
  • The inclusion of FCM’s nominees on our WHITE proxy card does NOT mean the Board endorses them.
  • Vote TODAY on the WHITE proxy card FOR all six of the Board’s nominees, WITHHOLD on FCM’s nominees and FOR the other proposals recommended by your Board.

Leading Proxy Advisory Firm Glass Lewis Recommends MindMed Shareholders Vote FOR All Six Company Nominees

Retrieved on: 
Thursday, June 8, 2023
Biotechnology, Finance, Health, Professional Services, Pharmaceutical, GAD, MindMed, NOT, ALL, Medicine, Glass Lewis, Annual general meeting, Patient, Glass, FDA, NEO, ISS, FCM, Management, Security (finance)

Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (NEO: MMED), (the “Company” or “MindMed”) today announced that leading proxy advisory firm Glass, Lewis & Co. (“Glass Lewis”) recommends shareholders vote for the election of ALL of MindMed’s six highly qualified director nominees to the Board of Directors (the “Board”) at the upcoming Annual Meeting of Shareholders (“Annual Meeting”), scheduled for June 15, 2023.

Key Points: 
  • Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (NEO: MMED), (the “Company” or “MindMed”) today announced that leading proxy advisory firm Glass, Lewis & Co. (“Glass Lewis”) recommends shareholders vote for the election of ALL of MindMed’s six highly qualified director nominees to the Board of Directors (the “Board”) at the upcoming Annual Meeting of Shareholders (“Annual Meeting”), scheduled for June 15, 2023.
  • Previously, leading proxy advisory firm Institutional Shareholder Services Inc. (“ISS”) also recommended in favor of all six of the Company’s director nominees.
  • Vote TODAY on the WHITE proxy card FOR all six of the Board’s nominees, WITHHOLD on FCM’s nominees and FOR the other proposals recommended by your Board.
  • Shareholders will receive proxy materials directly via the preferred method, hard copy or email, specific to each shareholder’s account.

MindMed to Host Investor Day June 2023

Retrieved on: 
Wednesday, June 7, 2023
Biotechnology, Pharmaceutical, Health, Neurology, GAD, MindMed, NEO, Medicine, Pharmaceutical industry

Mind Medicine (MindMed) Inc (NASDAQ: MNMD), (NEO: MMED), (the “Company” or “MindMed”), a clinical stage biopharmaceutical company developing novel product candidates to treat brain health disorders, announced today that its management team will a host an Analyst Day in New York City on Tuesday, June 20th, 2023 that will focus on the MM-120 program in generalized anxiety disorder (GAD).

Key Points: 
  • Mind Medicine (MindMed) Inc (NASDAQ: MNMD), (NEO: MMED), (the “Company” or “MindMed”), a clinical stage biopharmaceutical company developing novel product candidates to treat brain health disorders, announced today that its management team will a host an Analyst Day in New York City on Tuesday, June 20th, 2023 that will focus on the MM-120 program in generalized anxiety disorder (GAD).
  • In person attendance is by invitation only.
  • All others are invited to participate via the live webcast.

Leading Proxy Advisory Firm ISS Recommends MindMed Shareholders Vote FOR All Six Company Nominees

Retrieved on: 
Monday, June 5, 2023
Finance, Neurology, Public Relations, Investor Relations, Banking, Clinical Trials, Communications, Professional Services, Biotechnology, Pharmaceutical, Health, MindMed, Bruhn, Drug development, NOT, ALL, Medicine, AGM, University Hospital of Basel, Teaching hospital, Annual general meeting, Collection, Patient, Financial management, Mental health, NEO, ISS, FCM, Security (finance), Risk management, Management, Crystal, Vallone

Mind Medicine (MindMed) Inc. (NASDAQ: MNMD) (NEO: MMED), (the “Company” or “MindMed”) today announced that leading proxy advisory firm Institutional Shareholder Services Inc. (“ISS”) has recommended shareholders vote for ALL of MindMed’s six highly qualified director nominees at the upcoming Annual Meeting of Shareholders (“Annual Meeting”), scheduled for June 15, 2023.

Key Points: 
  • Mind Medicine (MindMed) Inc. (NASDAQ: MNMD) (NEO: MMED), (the “Company” or “MindMed”) today announced that leading proxy advisory firm Institutional Shareholder Services Inc. (“ISS”) has recommended shareholders vote for ALL of MindMed’s six highly qualified director nominees at the upcoming Annual Meeting of Shareholders (“Annual Meeting”), scheduled for June 15, 2023.
  • MindMed encourages all shareholders to follow the recommendation of ISS and vote "FOR" the Company's six highly qualified director nominees using the WHITE universal proxy card at the upcoming Annual Meeting, scheduled for June 15, 2023.
  • Vote TODAY on the WHITE proxy card FOR all six of the Board’s nominees, WITHHOLD on FCM’s nominees and FOR the other proposals recommended by your Board.
  • Shareholders will receive proxy materials directly via the preferred method, hard copy or email, specific to each shareholder’s account.

Cedar Clinical Research, by Numinus, the top enrolling clinical research site for MindMed's Phase 2B study evaluating MM-120

Retrieved on: 
Monday, June 5, 2023
Volunteering, CCR, TSX, Clinical trial, Principal, Research, Anxiety, MindMed, Nursing, Draper

CCR's research clinic in Draper, Utah, is the top enrolling site for the research study – having enrolled and dosed 19 clinical trial participants for the study to date.

Key Points: 
  • CCR's research clinic in Draper, Utah, is the top enrolling site for the research study – having enrolled and dosed 19 clinical trial participants for the study to date.
  • CCR also recently began enrolling volunteers for this trial at a second research clinic – in Murray, Utah.
  • "The fact that our Draper research clinic is the top enrolling site for the study underscores the quality of our clinical research capabilities and recruiting efforts."
  • To learn more about the study, and find out if you qualify to participate in it, please visit: https://www.anxietyresearchstudy.com/

FCM Predicts Psychedelic Revolution In 2024: Urges Shareholders to Position MindMed for Success with a Reconstituted Board

Retrieved on: 
Friday, June 2, 2023
Drug, BLUE, Multidisciplinary Association for Psychedelic Studies, ALL, Biotechnology, LSD, Attention, Psychedelic drug, Post-traumatic stress disorder, Research, FDA, Letter, Second Half, MDMA, PTSD, MindMed, FCM, Pharmaceutical industry, Management, Compass

SHERIDAN, Wyo., June 02, 2023 (GLOBE NEWSWIRE) -- FCM MM Holdings, LLC (“FCM”), published an open letter to the shareholders of Mind Medicine (MindMed) Inc. (NASDAQ: MNMD) (“MindMed”, the “Company”) from MindMed’s co-founder Dr. Scott Freeman. The letter highlights Dr. Freeman’s prediction that a revolution in psychedelic medicine will likely occur by the end of 2024, heralded by the FDA’s likely approval of Multidisciplinary Association for Psychedelic Studies’ (“MAPS”) drug, MDMA, for post-traumatic stress disorder (PTSD).

Key Points: 
  • Dr. Freeman emphasizes his belief that for MindMed to be able to fully participate in the coming psychedelic medicine revolution it must have a healthy balance sheet.
  • FCM believes that by cutting costs and doubling-down MindMed’s investment in its flagship drug LSD (MM-120) this is achievable.
  • It is critical that MindMed be fully prepared to be part of this revolution and the increased potential value and opportunities in the psychedelic industry.
  • In contrast, FCM has budgeted an estimated $39 million in annual operating expenses by keeping MindMed lean and efficient.

MindMed to Participate at Upcoming Investor Conferences

Retrieved on: 
Thursday, June 1, 2023
Biotechnology, Neurology, Health, Pharmaceutical, Clinical Trials, NEO, Medicine, MindMed, Pharmaceutical industry

Mind Medicine (MindMed) Inc (NASDAQ: MNMD), (NEO: MMED), (the “Company” or “MindMed”), a clinical stage biopharmaceutical company developing novel product candidates to treat brain health disorders, announced today that members of the Company’s management team will participate in the following investor conferences:

Key Points: 
  • Mind Medicine (MindMed) Inc (NASDAQ: MNMD), (NEO: MMED), (the “Company” or “MindMed”), a clinical stage biopharmaceutical company developing novel product candidates to treat brain health disorders, announced today that members of the Company’s management team will participate in the following investor conferences:

FCM Pledges to Lock Up its MindMed Shares Until June 2025 to Demonstrate its Alignment with Fellow Shareholders and Confidence in its Plan to Restore MindMed

Retrieved on: 
Tuesday, May 30, 2023
BLUE, FOR, Commit, HAND2, Research, CMO, History, Risk, SEDAR, Letter, Mouth, MindMed, FCM, Security (finance), Management, Tobacco, Pharmaceutical industry

SHERIDAN, Wyo., May 30, 2023 (GLOBE NEWSWIRE) -- FCM MM Holdings, LLC ("FCM"), beneficially owning approximately 3.5% of the outstanding common shares of Mind Medicine (MindMed) Inc. (NASDAQ: MNMD) (“MindMed” or the “Company”), today announces it sent a letter to shareholders from Dr. Scott Freeman. The letter calls out MindMed’s incumbent Board’s and management’s efforts to distract shareholders rather than confront their history of poor performance and destruction of shareholder value. In addition, Dr. Freeman pledges to lock-up his MindMed shares in conjunction with FCM, Mr. Jake Freeman and FCM’s director candidates until June 15, 2025, if FCM’s slate of director candidates is elected.

Key Points: 
  • MindMed has serious problems including:
    a history of punitive and dilutive financings,
    ill-conceived and chronically delayed clinical trials.
  • We have a plan to realign costs to support research and development and start a Phase III clinical trial in 2023.
  • Vote FOR the FCM director candidates who have confidence in their plan to drive shareholder value and are putting you first.
  • Shareholders who have questions or require any assistance with their vote, please contact Okapi Partners LLC, at (855) 305-0856 or [email protected]

FCM Concerned MindMed’s Mismanagement Threatens Mental Health for Millions

Retrieved on: 
Thursday, May 25, 2023
BLUE, Drug development, FOR, Biotechnology, Clinical trial, LSD, CMO, Central nervous system, Plasma protein binding, SEDAR, MM, Security (finance), FDA, NOW, MindMed, FCM, Pharmaceutical industry

SHERIDAN, Wyo., May 25, 2023 (GLOBE NEWSWIRE) -- FCM MM Holdings, LLC ("FCM"), today announced that it published a presentation outlining the overwhelming case for change at Mind Medicine (MindMed) Inc. (NASDAQ: MNMD) (“MindMed”, the “Company”) and how to efficiently bring much needed mental health drugs to millions with mental health disorders amid MindMed’s announcements of clinical trial delays.

Key Points: 
  • SHERIDAN, Wyo., May 25, 2023 (GLOBE NEWSWIRE) -- FCM MM Holdings, LLC ("FCM"), today announced that it published a presentation outlining the overwhelming case for change at Mind Medicine (MindMed) Inc. (NASDAQ: MNMD) (“MindMed”, the “Company”) and how to efficiently bring much needed mental health drugs to millions with mental health disorders amid MindMed’s announcements of clinical trial delays.
  • In our view, this irresponsible spending behavior and mismanagement has jeopardized bringing needed treatment for mental health disorders as evidenced by the LSD (MM-120) trial delays and the shuttering of MM-110.
  • “I co-founded MindMed to help millions of people with mental health disorders.
  • MindMed recently hired Greenleaf Health, Inc. (“Greenleaf”), a paid consulting firm, to support MindMed’s agenda and discredit FCM’s proposals.

MindMed Releases Investor Presentation Highlighting How the Company is Unlocking the Power of Psychedelics for Patients and Shareholders

Retrieved on: 
Thursday, May 25, 2023
Mental Health, Health, Clinical Trials, General Health, Pharmaceutical, Biotechnology, NOT, Drug development, Medicine, Clinical trial, Multimedia, LSD, Annual general meeting, Patient, Risk, Financial management, NEO, MindMed, FCM, Management, Security (finance)

Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (NEO: MMED), (the “Company” or “MindMed”) today announced that it has released an investor presentation in connection with its 2023 Annual Meeting of Shareholders.

Key Points: 
  • Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (NEO: MMED), (the “Company” or “MindMed”) today announced that it has released an investor presentation in connection with its 2023 Annual Meeting of Shareholders.
  • View the full release here: https://www.businesswire.com/news/home/20230525005833/en/
    The presentation is available at www.ProtectMindMed.com or on the investor relations section of the Company’s website.
  • Robert Barrow, Chief Executive Officer and Director of MindMed, stated: “MindMed is at a pivotal inflection point.
  • Shareholders will receive proxy materials directly via the preferred method, hard copy or email, specific to each shareholder’s account.